CFRA Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $286

CFRA analyst Kevin Huang maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $237 to $286.

Benzinga · 01/31/2020 15:52

CFRA analyst Kevin Huang maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $237 to $286.